AUM-302, a novel triple PIM/PI3K/mTOR inhibitor, synergizes with RAS inhibition and impedes the growth of pancreatic ductal adenocarcinoma spheroids and organoids.
- DOI
- 10.3389/fphar.2026.1685433
- Published
- 2026
- Container
- Frontiers in pharmacology
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.3389/fphar.2026.1685433,
title = {AUM-302, a novel triple PIM/PI3K/mTOR inhibitor, synergizes with RAS inhibition and impedes the growth of pancreatic ductal adenocarcinoma spheroids and organoids.},
author = {Wen E and Vera C and Kesavan S and Kouassi F and LaComb JF and Zand N and Tuveson DA and Habowski AN and Baines AT and Bialkowska AB},
year = {2026},
journal = {Frontiers in pharmacology},
doi = {10.3389/fphar.2026.1685433},
url = {https://doi.org/10.3389/fphar.2026.1685433}
}RIS
TY - JOUR TI - AUM-302, a novel triple PIM/PI3K/mTOR inhibitor, synergizes with RAS inhibition and impedes the growth of pancreatic ductal adenocarcinoma spheroids and organoids. AU - Wen E AU - Vera C AU - Kesavan S AU - Kouassi F AU - LaComb JF AU - Zand N AU - Tuveson DA AU - Habowski AN AU - Baines AT AU - Bialkowska AB PY - 2026 JO - Frontiers in pharmacology DO - 10.3389/fphar.2026.1685433 UR - https://doi.org/10.3389/fphar.2026.1685433 ER -
APA
E, W., C, V., S, K., F, K., JF, L., N, Z., DA, T., AN, H., AT, B., & AB, B. (2026). AUM-302, a novel triple PIM/PI3K/mTOR inhibitor, synergizes with RAS inhibition and impedes the growth of pancreatic ductal adenocarcinoma spheroids and organoids.. Frontiers in pharmacology. https://doi.org/10.3389/fphar.2026.1685433
Source records
- pubmed · retrieved 2026-09-25T13:10:26.952Z